SCHEMBL1032629

SCHEMBL1032629

CCCNCCOc1ccc(NS(=O)(=O)c2ccc(OC(F)F)cc2)c(OC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
TSHR P16473 2/20 0.39
HTT P42858 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KIT P10721 2/20 0.39
ST14 Q9Y5Y6 2/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
PRSS1 P07477 1/20 0.38
PRSS2 P07478 1/20 0.38
PRSS3 P35030 1/20 0.38
SQSTM1 Q13501 2/20 0.36
KEAP1 Q14145 2/20 0.36
NFE2L2 Q16236 2/20 0.36
KMT2A Q03164 4/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GLO1 Q04760 1/20 0.36
SLC40A1 Q9NP59 1/20 0.36
PKM P14618 3/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4240174 0.99 LMNA (0.39) LMNATSHRHTTSMN1; SMN2KIT
SCHEMBL1030310 0.90 TSHR (0.41) LMNATSHRHTTSMN1; SMN2ST14
Hydrochloric Acid SCHEMBL4246986 0.89 TSHR (0.40) LMNATSHRHTTSMN1; SMN2ST14
SCHEMBL1029498 0.89 KIT (0.41) LMNATSHRHTTSMN1; SMN2KIT
SCHEMBL1032791 0.88 TSHR (0.44) LMNATSHRHTTSMN1; SMN2ST14
Hydrochloric Acid SCHEMBL4243947 0.88 KIT (0.41) LMNATSHRHTTSMN1; SMN2KIT
SCHEMBL1031476 0.87 FFAR4 (0.40) LMNATSHRHTTSMN1; SMN2ST14
Hydrochloric Acid SCHEMBL4245486 0.87 TSHR (0.44) LMNATSHRHTTSMN1; SMN2ST14
SCHEMBL1031793 0.86 LMNA (0.35) LMNATSHRHTTSMN1; SMN2ST14
SCHEMBL1027217 0.86 LMNA (0.35) LMNATSHRHTTSMN1; SMN2ST14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013179-B1 ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-01-19 EP disclosed